Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2327 - Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Masato Nakamura

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

M. Nakamura1, A. Takashima2, T. Denda3, M. Gamoh4, I. Iwanaga5, Y. Komatsu6, M. Takahashi7, H. Ohori8, T. Sekikawa9, M. Tsuda10, Y. Kobayashi11, Y. Miyamoto12, M. Kotake13, C. Ishioka7, K. Shimada14, A. Sato15, S. Yuki16, S. Morita17, S. Takahashi7, T. Yamaguchi18

Author affiliations

  • 1 Comprehensive Cancer Center, Aizawa Hospital, 390-8510 - Matsumoto/JP
  • 2 Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3 Division Of Gastroenterology, Chiba Cancer Center Hospital, 260-8717 - Chiba/JP
  • 4 Department Of Medical Oncology, Osaki Citizen Hospital, 989-6183 - Osaki/JP
  • 5 Department Of Medical Oncology, Kitami Red Cross Hospital, 090-0026 - Kitami/JP
  • 6 Cancer Center, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 7 Department Of Medical Oncology, Tohoku University Hospital, 980-8575 - Sendai/JP
  • 8 Medical Oncology, Ishinomaki Red Cross Hospital, 986-8522 - Ishinomaki/JP
  • 9 Division Of Medical Oncology, Showa University Northern Yokohama Hospital, 224-8503 - Kanagawa/JP
  • 10 Department Of Gastroenterological Oncology, Hyogo Cancer Center, 673-8558 - Hyogo/JP
  • 11 Department Of Medical Oncology, Kushiro Rosai Hospital, 085-8533 - Kushiro/JP
  • 12 Department Of Gastroenterlogical Surgery, Graduate School of Medical Sciences, Kumamoto University, 860-8556 - Kumamoto/JP
  • 13 Department Of Surgery, Kouseiren Takaoka Hospital, 933-8555 - Toyama/JP
  • 14 Department Of Internal Medicine,division Of Medical Oncology, Showa University Kouto-Toyosu Hospital, 135-8577 - Tokyo/JP
  • 15 Department Of Medical Oncology, Hirosaki University Graduate School of Medicine, 036-8562 - Aomori/JP
  • 16 Gastroenterology And Hepatology, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 17 Department Of Biomedical Statistics And Bioinformatics, Kyoto University Graduate School of Medicine, 606-8507 - Kyoto/JP
  • 18 Department Of Surgery/hereditary Tumor Research Project, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 113-0021 - Tokyo/JP
More

Resources

Abstract 2327

Background

The TRICOLORE trial previously demonstrated that S-1 and irinotecan (IRI) plus bevacizumab (Bmab) was non-inferior to mFOLFOX6 or CapeOX plus Bmab in terms of progression-free survival (PFS) as first-line treatment for metastatic colorectal cancer (mCRC), irrespective of RAS status (Komatsu Y, et al. ESMO 2017, and Yamada Y, et al. Ann Oncol. 2018). We now report the final overall survival (OS) after a median follow-up of more than 3 years. The results of this trial were subjected to an exploratory analysis to determine if primary tumor location (TL) influenced the response to S-1 and IRI plus Bmab.

Methods

This trial was a randomized, open-label, phase 3 trial. Chemotherapy-naïve patients with mCRC were randomly assigned to receive either mFOLFOX6 or CapeOX plus Bmab (arm A) or S-1 and IRI plus Bmab (arm B, given as a 3-week regimen [7.5 mg/kg Bmab, 150 mg/m2 IRI on day 1, and 40 − 60 mg S-1 twice daily for 2 weeks, followed by a 1-week rest] or a 4-week regimen [5 mg/kg Bmab, 100 mg/m2, IRI on days 1 and 15, and 40 − 60 mg S-1 twice daily for 2 weeks, followed by a 2-week rest). Patients’ data were finally updated in September 2017.

Results

At this final analysis, the median overall survival (mOS) was 32.6 months with arm A and 34.3 months with arm B (median follow-up, 48.7 months). The hazard ratio (HR) for OS was 0.89 (95% CI: 0.72 − 1.10). Median progression-free survival (mPFS) in arm A/B were 10.8/14.0 months (HR 0.86, 95% CI: 0.71–1.04, p < 0.0001 for non-inferiority). In right-sided TL, mOS and mPFS in arm A/B were 25.6/28.1 months (HR 0.82, 95% CI 0.56-1.21) and 9.6 /11.4 months (HR 0.85, 95% CI 0.60-1.22), respectively. In left-sided TL, mOS and mPFS in arm A/B were 35.5/36.8 months (HR 0.89, 95% CI 0.68-1.15) and 11.3/15.0 months (HR 0.82, 95% CI 0.66-1.03), respectively.

Conclusions

Our updated analysis reconfirmed that S-1 and IRI plus Bmab is non-inferior to mFOLFOX6 or CapeOX plus Bmab in terms of PFS. S-1 and IRI plus Bmab is now recommended as a 1st-line treatment for mCRC irrespective of primary TL and RAS status.

Clinical trial identification

UMIN000007834.

Legal entity responsible for the study

Tokyo Cooperative Oncology Group (TCOG).

Funding

Taiho Pharmaceutical Co. Ltd.

Editorial Acknowledgement

Disclosure

A. Takashima: Corporate-sponsored research: Taiho, Takeda. T. Denda: Corporate-sponsored research: Sanofi, Boehringer Ingelheim, MSD. M. Gamoh: Corporate-sponsored research: Chugai, Taiho, Daiichi Sankyo, Yakult. Y. Komatsu: Other substantive relationships: Taiho Pharmaceutica, Lilly, MSD, Ono Pharmaceutical, Novartis, Chugai Pharma, Yakult, Merck Serono, Pfizer, Bayer. M. Takahashi: Corporate-sponsored research: Ono Yakuhin, MSD; Other substantive relationships: Ono Yakuhin, Chugaim Merck-Serono, Daiichi-Sankyo, Nihon-kayaku, Yakult, Taiho, Eli Lilly, Kyowa-Kirin. C. Ishioka: Corporate-sponsored research: Mochida, Kyowa-Kirin, Eizai, Chugai, Tsumura, Novartis, Merck-Serono, Daiichi-Sankyo, Takeda, Nihon-Kayaku, Yakult, Taiho, Ono, Astellas, Asahikasei-Parma, Kissei, Bristol other substantive relationships: Mochida, Chugai, Novartis, Merck-Serono, Daiichi-Sankyo, Takeda, Nihon-Kayaku, Yakult, Taiho, Ono, Asahikasei-Parma, Eli Lilly, Bayer. A. Sato: Membership on an advisory board or board of directors: Taiho Pharmaceutical Co., Ltd., Chugai Pharma Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd.; Corporate-sponsored research: Taiho Pharmaceutical Co., Ltd., Chugai Pharma Co., Ltd. S. Yuki: Honoraria: Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Bayer Yakuhin, Ltd., Taiho Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Merck Serono Co., Ltd., Sanofi Co. Ltd. S. Morita: Corporate-sponsored research: Taiho; Honorarium: Taiho. T. Yamaguchi: Honorarium: Taiho. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings